ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

44.51
-2.06
(-4.42%)
Closed February 25 3:00PM
44.99
0.48
( 1.08% )
Pre Market: 3:55AM
Advanced chart
Rendering Error

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
44.99
Bid
44.61
Ask
45.14
Volume
2,364
0.00 Day's Range 0.00
36.52 52 Week Range 90.62
Market Cap
Previous Close
44.51
Open
-
Last Trade
1
@
44.96
Last Trade Time
03:56:29
Financial Volume
-
VWAP
-
Average Volume (3m)
2,194,251
Shares Outstanding
85,774,474
Dividend Yield
-
PE Ratio
-24.85
Earnings Per Share (EPS)
-1.79
Revenue
371.21M
Net Profit
-153.61M

About CRISPR Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi... CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Zug, Che
Founded
-
CRISPR Therapeutics AG is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRSP. The last closing price for CRISPR Therapeutics was US$44.51. Over the last year, CRISPR Therapeutics shares have traded in a share price range of US$ 36.52 to US$ 90.62.

CRISPR Therapeutics currently has 85,774,474 shares outstanding. The market capitalization of CRISPR Therapeutics is US$3.82 billion. CRISPR Therapeutics has a price to earnings ratio (PE ratio) of -24.85.

CRISPR Therapeutics (CRSP) Options Flow Summary

Overall Flow

Bullish

Net Premium

591k

Calls / Puts

333.33%

Buys / Sells

18.18%

OTM / ITM

116.67%

Sweeps Ratio

0.00%

CRSP Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-7.33-14.009938837952.3255.8844.02295315649.37075154CS
43.147.5029868578341.8555.8838.28272059445.98835783CS
12-6.4-12.45378478351.3955.8836.52219425144.15447508CS
26-4.16-8.4638860630749.1559.069336.52170486046.14395706CS
52-38.51-46.11976047983.590.6236.52153421052.70439639CS
156-14.58-24.475407084159.5791.136.52153746557.56797753CS
260-4.98-9.9659795877549.97220.2132147784277.04664192CS

CRSP - Frequently Asked Questions (FAQ)

What is the current CRISPR Therapeutics share price?
The current share price of CRISPR Therapeutics is US$ 44.99
How many CRISPR Therapeutics shares are in issue?
CRISPR Therapeutics has 85,774,474 shares in issue
What is the market cap of CRISPR Therapeutics?
The market capitalisation of CRISPR Therapeutics is USD 3.82B
What is the 1 year trading range for CRISPR Therapeutics share price?
CRISPR Therapeutics has traded in the range of US$ 36.52 to US$ 90.62 during the past year
What is the PE ratio of CRISPR Therapeutics?
The price to earnings ratio of CRISPR Therapeutics is -24.85
What is the cash to sales ratio of CRISPR Therapeutics?
The cash to sales ratio of CRISPR Therapeutics is 10.28
What is the reporting currency for CRISPR Therapeutics?
CRISPR Therapeutics reports financial results in USD
What is the latest annual turnover for CRISPR Therapeutics?
The latest annual turnover of CRISPR Therapeutics is USD 371.21M
What is the latest annual profit for CRISPR Therapeutics?
The latest annual profit of CRISPR Therapeutics is USD -153.61M
What is the registered address of CRISPR Therapeutics?
The registered address for CRISPR Therapeutics is BAARERSTRASSE 14, ZUG, 6300
What is the CRISPR Therapeutics website address?
The website address for CRISPR Therapeutics is www.crisprtx.com
Which industry sector does CRISPR Therapeutics operate in?
CRISPR Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QVCGBQVC Group Inc
US$ 15.70
(209.06%)
858.39k
ENVBEnveric Biosciences Inc
US$ 2.53
(114.41%)
9.83M
PITAHeramba Electric PLC
US$ 0.73
(97.83%)
10.3M
LSBKLake Shore Bancorp Inc
US$ 25.47
(59.11%)
4
BSBKBogota Financial Corporation
US$ 12.40
(56.57%)
188
ADVMAdverum Biotechnologies Inc
US$ 1.73
(-58.81%)
21
HCATHealth Catalyst Inc
US$ 2.24
(-54.75%)
3
CSPICSP Inc
US$ 9.12
(-41.87%)
4
SRBKSR Bancorp Inc
US$ 7.01
(-41.83%)
7
SYRESpyre Therapeutics Inc
US$ 12.13
(-41.26%)
201
PITAHeramba Electric PLC
US$ 0.73
(97.83%)
10.3M
ENVBEnveric Biosciences Inc
US$ 2.53
(114.41%)
9.83M
HCTIHealthcare Triangle Inc
US$ 0.5935
(56.18%)
6.25M
ONVOOrganovo Holdings Inc
US$ 1.53
(20.47%)
3.87M
QVCGAQVC Group Inc
US$ 0.49
(27.60%)
3.27M

CRSP Financials

Financials
Rendering Error

CRSP Discussion

View Posts
jondoeuk jondoeuk 4 days ago
Looks pretty bullish for Casgevy https://www.businesswire.com/news/home/20250221469479/en/bluebird-bio-Announces-Definitive-Agreement-to-be-Acquired-by-Carlyle-and-SK-Capital
👍️0
TechandBio TechandBio 1 week ago
Added a chunk today to my stash average is now 42.00

$CRSP
👍️0
TechandBio TechandBio 1 week ago
Nice pre market action!

Very deep pipeline with a mega partner VRTX

$CRSP
👍️0
TechandBio TechandBio 2 weeks ago
Starting to turn the corner now!

Glad I re-loaded the low 40's

$CRSP
👍️ 1
jondoeuk jondoeuk 1 month ago
Anticipated 2025 milestones https://www.globenewswire.com/news-release/2025/01/13/3008308/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2025-Milestones.html
👍️ 1
jondoeuk jondoeuk 1 month ago
Link to the webcast https://jpmorgan.metameetings.net/events/healthcare25/sessions/58421-crispr-therapeutics/webcast/general_signin?gpu_only=true&kiosk=true+%5Bjpmorgan.metameetings.net%5D
👍️ 1
jondoeuk jondoeuk 2 months ago
They will present at the 43rd Annual J.P. Morgan Healthcare Conference (Jan 14, at 2:15 PM PST).
👍️ 1
PonkenPlonken PonkenPlonken 3 months ago
cheap cheap
👍️ 1
jondoeuk jondoeuk 3 months ago
The PR https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html

Poster https://ir.crisprtx.com/static-files/12114290-21a6-4544-9cb7-de4fe2852e94
👍️0
PonkenPlonken PonkenPlonken 3 months ago
Neglected ugly duckling. $NTLA, $VERV & $CRBU now do trials outside of the US.... Maybe sentiment change is on the horizon -- see below

"The CBER director also apologized for “mistakes” in how the FDA handled early work for in vivo gene therapies, which “led to offshoring of some of the trials.”"
https://endpts.com/fda-vaccine-chief-peter-marks-pledges-to-stay-as-long-as-hes-welcome/#:~:text=The%20CBER%20director%20also%20apologized,%E2%80%9Cit%20is%20really%20important.%E2%80%9D

CHEAP CHEAP
SRPT and BMS announcing nice CRISPR deals with ARWR and PRME should help this too!
👍️0
jondoeuk jondoeuk 3 months ago
CTX130 data in R/R T-cell lymphomas (peripheral T-cell lymphoma or cutaneous T-cell lymphoma) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract

The ORR was 46.2%. Of those treated at DL3 and higher, the ORR was 51.6%.
👍️ 1
PonkenPlonken PonkenPlonken 3 months ago
so so so undervalued and misunderstood i believe...... frankly just cheap
https://x.com/RNAiAnalyst/status/1859876294487363651
👍️ 1
jondoeuk jondoeuk 3 months ago
They now have the ability to put in eight to nine edits. So it is a single cassette that expresses the CAR, can express a cytokine and has an shRNA-like approach to knock down genes. So there's no theoretical limit as to the number of edits, but there may be marginal utility beyond a certain point.

Hopefully, they look to improve donor selection, cell selection and manufacturing, as all could increase efficacy.
👍️ 1
jondoeuk jondoeuk 4 months ago
ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html
👍️0
jondoeuk jondoeuk 4 months ago
Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html
👍️0
Monksdream Monksdream 4 months ago
CRSP 10Q 11/5
👍️0
Monksdream Monksdream 4 months ago
CRSP under $50
👍️0
jondoeuk jondoeuk 4 months ago
OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082
👍️ 1
TechandBio TechandBio 5 months ago
CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html
👍️0
Monksdream Monksdream 5 months ago
Buy range again thanks a bunch
👍️0
Monksdream Monksdream 5 months ago
Buy range again thanks a bunch
👍️0
OldAIMGuy OldAIMGuy 5 months ago
Hi MD,
Here's a little longer view:


This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG
👍️0
Monksdream Monksdream 5 months ago
CRSP trend since February remains bearish
👍️0
jondoeuk jondoeuk 7 months ago
Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html
👍️0
lambchops lambchops 7 months ago
Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!
👍️0
Monksdream Monksdream 7 months ago
CRSP under $75
👍️0
TechandBio TechandBio 8 months ago
Crispr added some $120 Vertical debit spreads in 2026

$CRSP
👍️ 1
axelvento axelvento 9 months ago
I agree.....solid company$$$$$$$$
👍️0
Monksdream Monksdream 9 months ago
It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero
👍️ 1
axelvento axelvento 10 months ago
Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html
👍️0
jondoeuk jondoeuk 10 months ago
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
👍️0
jondoeuk jondoeuk 10 months ago
Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html
👍️0
jondoeuk jondoeuk 10 months ago
Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html
👍️0
jondoeuk jondoeuk 10 months ago
https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html
👍️0
OldAIMGuy OldAIMGuy 11 months ago
StockCharts 3 year history with 20% ZigZag reversals................



CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG
👍️0
OldAIMGuy OldAIMGuy 11 months ago
Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG
👍️0
Monksdream Monksdream 11 months ago
CRSP over $30
👍️0
jondoeuk jondoeuk 11 months ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html
👍️0
Monksdream Monksdream 1 year ago
CRSP new 52 week high
👍️0
Monksdream Monksdream 1 year ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 1 year ago
CRSP new 52 week high
👍️ 1
Monksdream Monksdream 1 year ago
CRSP new 52 week high
👍️ 1
jondoeuk jondoeuk 1 year ago
They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html
👍️0
jondoeuk jondoeuk 1 year ago
EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html
👍️ 1
Monksdream Monksdream 1 year ago
Didn’t tank like BLUE
Recovered


More analysis from Nanolyze

👍️0
Monksdream Monksdream 1 year ago
So there has been some discussion since my last post
More in this podcast
🌈 1 🍆 1
jondoeuk jondoeuk 1 year ago
Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html
👍️ 1
jondoeuk jondoeuk 1 year ago
Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html
👍️0
jondoeuk jondoeuk 1 year ago
Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true
👍️ 1
jondoeuk jondoeuk 1 year ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html
👍️0

Your Recent History

Delayed Upgrade Clock